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Background: Gene therapy for people with hemophilia (PWH) will soon become 
available outside current clinical trials. The World Federation of Hemophilia (WFH), 
in collaboration with International Society of Thrombosis and Hemostasis Scientific 
and Standardization Committee (ISTH SSC), the European Haemophilia Consortium 
(EHC), the US National Hemophilia Foundation (NHF), the American Thrombosis 
and Hemostasis Network (ATHN), industry gene therapy development partners and 
Regulatory liaisons have developed the Gene Therapy Registry (GTR), designed to 
collect long-term data on all PWH who receive hemophilia gene therapy.
Objective: The objectives of the GTR are to record the long-term safety and efficacy 
data post gene therapy infusion and to assess the changes in quality of life and bur-
den of disease post-gene-therapy infusion.
Methods: The GTR is a prospective, observational, and longitudinal registry devel-
oped under the guidance of a multi-stakeholder GTR Steering Committee (GTR SC), 
composed of health care professionals, patient advocates, industry representatives, 
and regulatory agency liaisons. All PWH who receive gene therapy by clinical trial or 
commercial product will be invited to enrol in the registry through their hemophilia 
treatment centers (HTCs). The registry aims to recruit 100% of eligible post gene 
therapy PWH globally. Through an iterative process, and following the guidance of 
the European Medicines Agency (EMA) and the US Food and Drug Administration 
(FDA), the GTR SC has developed a core set of data to be collected on all patients 
post gene therapy.
Results: The core data set includes demographic information, vector infusion details, 
safety, efficacy, quality of life and burden of disease.
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1  | BACKGROUND AND STR ATEGY
The first gene therapy product for people with hemophilia (PWH) is ex-
pected to receive regulatory approval in 2020, with several additional 
approvals close on the horizon. Current data on these emerging tech-
nologies suggest a potential “functional cure,” with bleeding essentially 
eliminated in the majority of treated hemophilia patients.1-3 Although 
the potential for these transformative gene therapies is great, emerg-
ing technologies by definition have unknown safety and efficacy risks.4 
Most of these gene therapies will be evaluated and approved based 
on small cohort trial enrollment with limited duration follow-up. This 
imposes a heavy reliance on the postmarketing experience to gather 
critical evidence of safety and durability.5
Current late-phase gene therapy trials for hemophilia A and B are 
using an adeno-associated viral (AAV) vector for targeted in vivo he-
patocyte expression.1-3 Naturally occurring AAV is a member of the 
Parvoviridae family and is generally considered nonpathogenic.6 Although 
clinical trial data provide reassurance of short-term safety and efficacy 
of AAV-mediated gene therapy, we are entering this new treatment era 
with remaining questions of short- and long-term safety. Safety issues 
identified to date include hepatic inflammation, due, at least in part, to an 
AAV capsid-mediated immune response, and a febrile reaction that may 
occur usually within 48 hours of vector infusion.4,7,8 The asymptomatic 
increase in liver transaminases is generally vector dose-dependent and 
usually, but not always, responsive to a course of steroid therapy. The 
optimal approach to immunosuppression in this setting has yet to be de-
fined and prophylactic regimens are being evaluated.
Safety risks include currently unknown risks, but there are 
also known issues that will need to be monitored such as risks of 
long-term hepatic toxicity and genotoxicity, particularly in patients 
with prior viral infections, and the risk of insertional mutagenesis.4 
Although AAV is predominantly a nonintegrating virus, integra-
tion events demonstrated in large animal and humans, post-AAV 
gene transfers occur at an estimated frequency of approximately 
0.1% per transduced cell.4,7,9 Hepatocellular carcinoma was seen 
in one liver-directed recombinant AAV preclinical murine study10; 
a larger study found that hepatocellular carcinoma risk depended 
upon vector dose, promotor, enhancer, and the degree of hepatic 
cell division during vector administration.11 A 10-year follow-up of 
AAV-mediated factor VIII (FVIII) expression in dogs detected inte-
gration events and evidence of clonal expansion in liver tissue, but 
there was no evidence of hepatocyte damage or tumorigenesis.12 
The only available study of human liver tissue postintravascular 
AAV delivery demonstrated evidence of random integration events 
without evidence of genotoxicity or clonal expansion.9
At this point, it is unknown how long a gene therapy effect will 
persist. Factor IX activity has persisted at stable levels of ~5% in the 
high-dose cohort of the St. Jude/UCL phase 1/2 trial with more than 
9 years of follow-up.3 Whether similar long-term stable expression 
will be seen in trials currently achieving higher FIX levels through 
the use of the FIX Padua construct has yet to be shown, although 
initial results are promising.3,8 In patients with 3 years of follow-up 
after F8 gene therapy (AAV5-hFVIII-SQ), some of whom initially 
had levels well into or above the normal range, the median chromo-
genic FVIII activity was 20% in the highest dose cohort (6 × 1013 vg/
kg).13 Whether levels will stabilize or gradually fall is unknown. In 
terms of efficacy measured by bleeding events, overall, most trials 
have shown a remarkable decrease in bleeding and factor usage and 
improved quality of life.1-3,7,8,13 However, only longer term data will 
answer the questions around efficacy and durability and identify dif-
ferences should they exist by vector or transgene used.
Conclusions: The GTR is a global effort to ensure that long term safety and efficacy 
outcomes are recorded and analysed and rare adverse events, in a small patient popu-
lation, are identified. Many unknowns on the long-term safety and efficacy of gene 
therapy for hemophilia may also be addressed.
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Ultimately, the accumulation of patient exposure captured in 
long-term registries is the most likely means of revealing unexpected 
events associated with this new technology. Detecting low incident 
or delayed safety events, particularly in small treatment cohorts of 
a rare disease, necessitates that each PWH who receives gene ther-
apy be followed over the long term, preferably their lifetime, in a reg-
istry that has as its goal inclusion of all treated patients. Additional 
approaches to gene therapy for hemophilia are under study in pre-
clinical and early clinical models including use of gene-editing, lenti-
viral vector, and cellular therapies.3,8,14 These will carry common and 
unique risks and benefits compared with AAV-mediated gene ther-
apy and postmarketing surveillance will need to be adaptable to new 
safety signals and new endpoints as the field evolves.15 Additionally, 
registration trials are being performed in a healthy subset of patients, 
and restrict use of comedications, thereby reducing the likelihood of 
detecting disease–drug and drug–drug interactions.16
A collaborative global strategy is required to ensure a large 
enough patient pool to allow robust evaluation and detection of 
low incident events that may otherwise go undetected. If events are 
captured in disparate registries or databases, we will regrettably not 
benefit from the power of combined data. As the field continues to 
make progress, a growing set of long-term safety and efficacy data 
will ultimately define the future of gene therapy in hemophilia. For 
a long-lasting, potentially life-long, therapy, we need data collection 
over the lifespan of treated patients, longer than the mandated fol-
low up by the US Food and Drug Administration of 5 years.17
The World Federation of Hemophilia (WFH), working with the 
International Society on Thrombosis and Hemostasis (ISTH), along with 
the European Haemophilia Consortium, the US National Hemophilia 
Foundation, the American Thrombosis and Hemostasis Network 
(ATHN), industry developer partners, and regulatory liaisons, is devel-
oping a global gene therapy registry. This registry will use a core data 
set, with input from a multistakeholder steering committee. Guidance 
from the US Food and Drug Administration and European Medicines 
Agency has informed the registry and specific data elements.17-19
Areas of focus of the core data set are shown in Table 1 and the full 
data set in Table S1. The aim of the gene therapy registry project is to 
provide a core data set integrated into a robust, scientifically valid reg-
istry, which is available to all physicians treating PWH who receive gene 
therapy. A patient mobile application will integrate patient reported out-
comes directly into the registry. The data stemming from this registry will 
provide for robust surveillance of safety and efficacy of gene therapy.
2  | IMPLEMENTATION OF THE WFH GENE 
THER APY REGISTRY
The WFH gene therapy registry is a prospective, observational, and lon-
gitudinal registry. All PWH who receive gene therapy, via clinical trial 
or postregulatory approval, will be encouraged to participate, with an 
aim to enroll nearly 100% of eligible PWH globally. Patients who do 
not provide informed consent to participate will be asked to give the 
reason to account for potential selection bias in enrollment. Clinical trial 
participants will be enrolled following the closure of their trials, and 
postapproval PWH will be enrolled at the time of vector infusion.
Widespread successful implementation of this global registry is 
critical to its success. Outreach activities to educate hemophilia pro-
viders and PWH about the importance of surveillance are beginning. 
The WFH will collaborate with individual hemophilia treatment cen-
ters (HTCs) and existing gene therapy registries to leverage estab-
lished data repositories. As an example, in the United States, ATHN is 
developing a gene therapy study (ATHN-14: Hemophilia Gene Therapy 
Outcomes Study) and working with the WFH to ensure harmonized 
data collection between the two registries. Where collaboration with 
an existing gene therapy registry is not currently available, HTCs par-
ticipating in gene therapy trials, HTCs with plans to become an in-
fusion center postregistration as well as HTCs that will follow their 
patients who have received gene therapy at an infusion center, are 
being contacted to plan for implementation. Financial reimbursement 
for provider and patient effort and expenses is planned. Integrating 
the collection of data into the clinical practice of physicians and the 
daily lives of PWH, requires a harmonious and uniform data collection 
methodology, that will be accepted and used by all stakeholders.
Data from this global gene therapy registry will be critical to an-
swer questions regarding safety and efficacy of gene therapy in he-
mophilia. Given that hemophilia is a rare disease, it is imperative that 
we have a global approach to data collection to detect low incidence 
events that may affect the lives of PWH who choose to undergo gene 
therapy. The registry will also be able to measure and compare the 
impact of gene therapy on the lives of PWH around the world. Success 
of this ambitious initiative needs the support of all stakeholders. Only 
through cohesive efforts by all treating physicians, PWH, regulatory 
agencies and manufacturers worldwide, will we ensure that gene ther-
apy is safe and efficacious for our patients now, and in the future.
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